Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | PHGDH | O43175 | 2/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.59 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MLNR | O43193 | 2/20 | 0.48 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | UBE2M | P61081 | 1/20 | 0.47 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21958193 | 1.00 | KMT2A (0.62) | KMT2APHGDHEPHX2BTKRAB9A | |
| SCHEMBL30027279 | 0.89 | KMT2A (0.60) | KMT2APHGDHEPHX2BTKRAB9A | |
| SCHEMBL24781682 | 0.88 | EPHX2 (0.60) | KMT2APHGDHEPHX2RAB9AMLNR | |
| SCHEMBL25785164 | 0.88 | EPHX2 (0.61) | KMT2APHGDHEPHX2BTKRAB9A | |
| SCHEMBL25785151 | 0.88 | EPHX2 (0.61) | KMT2APHGDHEPHX2BTKRAB9A | |
| SCHEMBL21958715 | 0.86 | TEAD1 (0.62) | KMT2APHGDHEPHX2BTKRAB9A | |
| SCHEMBL21958750 | 0.86 | TEAD1 (0.62) | KMT2APHGDHEPHX2BTKRAB9A | |
| SCHEMBL24781306 | 0.86 | KMT2A (0.59) | KMT2APHGDHEPHX2BTKRAB9A | |
| SCHEMBL30028550 | 0.86 | KMT2A (0.59) | KMT2APHGDHEPHX2BTKRAB9A | |
| SCHEMBL17927228 | 0.86 | KMT2A (0.59) | KMT2APHGDHEPHX2BTKRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| WO-2020081572-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | KMT2A 2881/4885PHGDH 2187/4885EPHX2 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.